nm32-2668
Liposarcoma
Numab Therapeutics AGPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Liposarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Pfizer | Phase 2 | B |
Letrozole Pfizer | Phase 2 | CCC |
Enzalutamide Pfizer | Phase 2 | CCC |
Atirmociclib Pfizer | Phase 2 | CCC |
MIDAZOLAM Pfizer | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
nm32-2668 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →